Evidence map›Paper›PMID 36175881›Full record

ArticleBMC endocrine disorders2022

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.

Vanessa C Brunetti, Audray St-Jean, Sophie Dell'Aniello, Anat Fisher, Oriana H Y Yu, Shawn C Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi-Severini, Baiju R Shah and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03939624. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03939624 completed

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and the Risk of Cardiovascular Events Among Patients With Type 2 Diabetes: a Multicenter Cohort Study

Ran2018Enrolled419,734Registered outcomes5Posted comparisons0ConditionsAll-Cause Mortality, Cardiovascular Death, Heart Failure, Ischemic StrokeArmsDipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sodium-glucose cotransporter 2 (SGLT2) inhibitors
PMID 34332563PMID 27610604PMID 32967856other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 2 countries.

Vanessa C BrunettiDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Audray St-JeanCenter for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada.
Sophie Dell'AnielloCenter for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada.
Anat FisherDepartment of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada.
Oriana H Y YuCenter for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada.
Shawn C BugdenCollege of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Jean-Marc DaigleInstitut national d'excellence en santé et en services sociaux (INESSS), Quebec, Quebec, Canada.
Nianping HuThe Health Quality Council, Saskatoon, Saskatchewan, Canada.
Silvia Alessi-SeveriniCollege of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Baiju R ShahICES, Toronto, Ontario, Canada.
Paul E RonksleyDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Lisa M LixDepartment of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Pierre ErnstCenter for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada.
Kristian B FilionDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. kristian.filion@mcgill.ca.
Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Jewish General Hospital · CADalhousie University · CAManitoba Health · CAUniversity of British Columbia · CAMcGill University Health Centre · CAUniversity of Calgary · CACentre Hospitalier de l’Université de Montréal · CAInstitut National d'Excellence en Santé et en Services Sociaux · CAMemorial University of Newfoundland · CASaskatchewan Health Quality Council · CASunnybrook Health Science Centre · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCharacteristics of patients using newer 2

methodsWe conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018.

resultsOur cohorts included 194,070 new users of DPP-4i, 166,722 new users of SGLT-2i, and 27,719 new users of GLP-1 RA. New users of GLP-1 RA were more likely to be younger (mean ± SD: 56.7 ± 12.2 years) than new users of DPP-4i (67.8 ± 12.3 years) or SGLT-2i (64.4 ± 11.1 years). In Canada, new users of DPP-4i were more likely to have a history of coronary artery disease (22%) than new users of SGLT-2i (20%) or GLP-1 RA (15%).

conclusionAlthough SGLT-2i, DPP-4i, and GLP-1 RAs are recommended as 2

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsSymportersCanadaCohort StudiesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucoseHumansHypoglycemic AgentsSodiumUnited KingdomDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucoseHypoglycemic AgentsSodiumSodium-Glucose Transporter 2 InhibitorsSymportersdipeptidyl peptidase 4 inhibitorsglucagon-like peptide 1 receptor agonistssodium-glucose co-transporter 2 inhibitorsType 2 diabetes

Identifiers

PMID36175881
PMCPMC9520836
OpenAlexW4298001471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.